The relative benefit of the currently approved maintenance therapies FLT3 inhibitors, oral azacitidine and HDC/IL-2 is likely dependent on disease characteristics including type of AML, intensity or effectiveness of previous therapy and age. This evidence concerns the gene FLT3 and acute myeloid leukemia.